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Novelty and impact: Using a bioinformatics approach we show that autoimmune diseases 
share genetic components with pancreatic cancer and further corroborate this association in a 
European case-control study population. Some of these results are confirmatory of the 
mechanisms of pancreatic carcinogenesis while others might point to novel mechanisms. This 
information could open new venues to explore and increase our understanding of PC risk, 
potentially impacting the prevention and treatment strategies for this deadly cancer.  
 
 
Deaths from pancreatic cancer are increasing making it a public health emergency to define 
the molecular causes of this deadly disease. Here the authors show that autoimmune diseases 
share genetic components with pancreatic cancer and further corroborate this association in a 
case-control study. This could bring new mechanistic understanding of pancreatic cancer, 
potentially impacting its prevention and treatment in the future.  
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Abstract  
 
Deciphering the underlying genetic basis behind pancreatic cancer (PC) and its associated 
multimorbidities will enhance our knowledge towards PC control. The study investigated the 
common genetic background of PC and different morbidities through a computational 
approach and further evaluated the less explored association between PC and autoimmune 
diseases (AIDs) through an epidemiological analysis. Gene-disease associations (GDAs) of 
26 morbidities of interest and PC were obtained using the DisGeNET public discovery 
platform. The association between AIDs and PC pointed by the computational analysis was 
confirmed through multivariable logistic regression models in the PanGen European case-
control study population of 1,705 PC cases and 1,084 controls. Fifteen morbidities shared at 
least one gene with PC in the DisGeNET database. Based on common genes, several AIDs 
were genetically associated with PC pointing to a potential link between them. An 
epidemiologic analysis confirmed that having any of the nine AIDs studied was significantly 
associated with a reduced risk of PC (Odds Ratio (OR)=0.74, 95% Confidence Interval (CI) 
0.58-0.93) which decreased in subjects having >2 AIDs (OR=0.39, 95%CI 0.21-0.73). In 
independent analyses, polymyalgia rheumatica and rheumatoid arthritis were significantly 
associated with low PC risk (OR=0.40, 95%CI 0.19-0.89, and OR=0.73, 95%CI 0.53-1.00, 
respectively). Several inflammatory-related morbidities shared a common genetic component 
with PC based on public databases. These molecular links could shed light into the molecular 
mechanisms underlying PC development and simultaneously generate novel hypotheses. In 
this study, we report sound findings pointing to an association between AIDs and a reduced 
risk of PC. 
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Introduction 
 
Pancreatic cancer (PC) is a deadly disease
1
 and projected to become the second cause of 
cancer-related death in Europe by 2030
2
, supporting its consideration as a public health 
emergency
3
. Patients with chronic pancreatitis, type 2 diabetes (T2D), or obesity have an 
increased risk of PC
4–6
 while those with nasal allergies and asthma have a reduced risk
7
. 
Multiple morbidities are common in ageing, a main risk factor of PC, but they are seldom 
studied in a contextual frame, which is important since multiple conditions can share adverse 
lifestyle and/or genetic susceptibility. In this respect, a higher risk of PC has been reported 
among subjects having >3 metabolic syndrome-related disorders or gastric conditions versus 
those having none of them
8,9
. Understanding the mechanisms shared between 
multimorbidities and PC could help improve primary prevention, early-diagnosis, prognosis 
and/or treatment of PC. Therefore, the combined use of well-annotated epidemiological and 
clinical datasets with bioinformatics tools becomes ideal to systematically explore the genetic 
complexity underlying the associations between different multimorbidities and PC. 
Autoimmune diseases (AIDs) are characterized by an immune dysregulation in which 
immune cells react against self-antigens resulting in cell and tissue damage. AIDs are 
classified into organ-specific and systemic depending on whether the autoimmune response is 
directed against a single or multiple tissues
10
. Cancer is thought to result from the 
accumulation of genetic alterations and the evasion of the immune response against 
neoantigens; therefore, it is conceivable that AIDs and cancer share genetic mechanisms. 
Studies have reported positive associations between overall cancer risk and AIDs such as 
celiac disease, Crohn‟s disease, rheumatoid arthritis, or systemic lupus erythematosus 11–13. 
However, contrary associations have been reported for specific types of cancer, e.g. positive 
associations have been observed for Non-Hodgkin‟s lymphom  with Crohn‟s disease, 
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rheumatoid arthritis, and lupus erythematosus, or liver cancer with celiac disease, ulcerative 
colitis, or inflammatory bowel disease 
12,14–17
, while other studies have reported negative 
associations between breast cancer with celiac disease, rheumatoid arthritis, and lupus 
erythematosus, or colorectal cancer with rheumatoid arthritis
18–21
. However, to date, limited 
and conflicting information exists regarding the association between autoimmunity and the 
risk of PC, which could be partly explained by the relatively low prevalence of both 
conditions in the population 
12,17,18,22,23
. 
In this study, we examine the genetic background shared between 26 candidate 
medical conditions and PC to identify underlying common genes using DisGeNET, a 
platform that integrates information on gene-disease associations from different public 
resources including the literature. Our aim was to generate novel genetic-based hypothesis 
regarding multimorbidities associated with PC as well as to obtain insight into their 
underlying molecular mechanisms. Finally, we sustain these observations through an 
epidemiological approach using the resources of a large international case-control study. 
 
Material and Methods 
 
The bioinformatics analysis was performed with disgenet2r version 3.1.2 
(https://bitbucket.org/ibi_group/disgenet2r), an R package that explores the molecular basis 
of comorbidities based on DisGeNET
24
 (version 3.0), a knowledge platform on human 
diseases and their association with gene alterations reported in UniProt, ClinVar, and CTD 
datasources.  
Disease vocabulary. To interrogate the DisGeNET database, diseases were defined as 
Concept Unique Identifiers (CUIs) from the Unified Medical Language Systems 
Metathesaurus. The CUIs for PC and 26 candidate morbidities were selected from three 
semantic types (disease or syndrome, sign or symptom and neoplastic process) by two 
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members of the group (PG and NM). A mean of 4 (range 1 to 12) CUIs were used to define 
each disease (Additional file 1: Table S1). All 26 candidate morbidities were included in the 
bioinformatics analysis based on their availability of epidemiological information in the 
PanGenEU study. 
DisGeNET query. For all but four conditions, the curated subset of DisGeNET was 
queried. Polymy lgi  rheum tic , mumps, pernicious  n emi ,  nd  ddison‟s dise se were 
not found in the curated data sources and thus were queried from all sources that include data 
automatically extracted from the literature using text mining approaches. The obtained genes 
were manually curated by a member of the group (PG). 
Disease association on the basis of shared genes. The number of common genes 
between dise se p irs w s used to determine dise se “genetic” simil rities. The J cc rd index 
(JI) was calculated to estimate the association among diseases accounting for variation in 
gene findings due differentially studied morbidities, i.e. diseases with more versus less total 
number of genes identified. The JI is defined  s: |Genesdis1 ∩ Genesdis2| / |Genesdis1 ∪  
Genesdis2|, where Genesdis1 and Genesdis2 are the genes associated with disease 1 and 2, 
respectively, ∩ is the intersection oper tor,  nd ∪  is the union operator between the two sets 
of genes. An empirical P value was calculated for each JI using 50,000 bootstrapped samples 
from a pool of the 7,878 disease genes available in DisGeNET (curated data set). 
Additionally, the Disease Specificity (DSI) and Pleiotropy (DPI) indexes were calculated 
(www.disgenet.org/web/DisGeNET/menu/dbinfo#specificity) to characterize all disease 
genes. Both indexes range from 0 to 1, where DSI = 1 implies high disease specificity (genes 
associate only with one disease) and DPI = 1 implies high disease pleiotropy (the gene is 
associated with several diseases and these belong to different classes).  
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Gene Ontology analysis. The Gene Ontology terms, restricted to the Biological 
Process (BP) branch, were identified through an enrichment analysis performed with the 
common genes between disease pairs with GO.db and GOstats packages in R.  
Pathway analysis. An enrichment analysis was performed using the ReactomePA 
package in R to identify pathways shared between morbidities based on common genes 
between disease pairs.  
 
The epidemiological analysis was performed using resources from the PanGenEU case-
control study conducted in Spain, United Kingdom, Germany, Ireland, Sweden, and Italy, 
between 2009-2014 (Additional file 1: Annex S1). 
Study population. Potentially eligible pancreatic ductal adenocarcinoma patients, men 
and women >18 years of age, were approached for participation. Subjects with diagnosis not 
confirmed by the physician were excluded from the study. Eligible controls did not have 
previous history of PC and their primary diagnosis for hospital admission was not associated 
with known risk factors of PC (Supplementary Table S1 and S2) when recruited in a hospital-
based setting; controls from Ireland and Sweden were population-based. Subjects without 
information in the entire medical section of the questionnaire were excluded (N=268, 8.8%) 
leaving 1,705 PC cases and 1,084 controls for analyses. Age, sex, and smoking distributions 
were similar between included and excluded subjects (P >0.05). An overall response rate of 
86.3% was observed for cases and 77.8% for controls. IRB ethical approval and written 
informed consent was obtained by all participating centers and study participants, 
respectively. 
Study variables. Demographics, lifestyle, and medical history were gathered through 
in-person interviews applying standardized questionnaires. Subjects reported “yes/no” to 
“H s your doctor ever told you th t you h d  ny of the following illnesses, he lth problems 
or procedures?” for 26 candidate morbidities including 9 AIDs further categorized as 
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systemic (rheumatoid arthritis, lupus erythematosus, scleroderma, and polymyalgia 
rheumatica), hematologic (pernicious anaemi ), g strointestin l (Crohn‟s dise se, ulcer tive 
colitis,  nd celi c dise se),  nd endocrine ( ddison‟s dise se). Regul r consumption of  nti-
inflammatory/pain killer medication (aspirin, paracetamol, NSAIDs and corticosteroids) was 
defined as subjects reporting ever taking one of these treatments at least once a week, on 
average, for 3 months or more.  
Statistical analysis. Imputation of missing values (3.7% in cases and 2.9% in controls) 
was performed with random forest (missForest R package). Missing values were assumed to 
be missing at random. Variables used for imputation (% missings) included case-control 
status, country, age (2.3%), sex (0.2%), smoking (pack/years, 9.4%), alcohol status (1.5%), 
medication (6.1- 7.9%), and morbidities and time since diagnosis (0.8%-21.7%). Imputation 
was performed with no maximum number of iterations and 100 trees. An imputation test 
introducing the same proportions of missing values to a complete-case dataset resulted in a 
concordance mean between imputed and real data >90% and out of bag errors < 0.35 (0= 
good imputation performance, 1= bad imputation performance). Multivariable logistic 
regression models were used to test the association between PC risk and AIDs, individually 
and by defined groups. Adjustment variables were selected based on the 10% change in 
estimate, the likelihood ratio tests and the Akaike Information Criterion (AIC). Potential 
confounders considered were smoking, alcohol, T2D, obesity, family history of PC, years of 
education, and treatment. Multicollinearity between variables was discarded based on 
variance-inflation factor threshold <2. Interactions with age, sex, smoking, alcohol and 
treatments were explored by including the interaction terms in the models. 
 
Results  
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The gene-disease association analysis based on publicly available information showed that all 
diseases except hypothyroidism, were connected through shared genes with at least one other 
morbidity (Additional file 1: Figure S1). The total number of genes associated with the 26 
non-cancer medical conditions averaged 41.3 ranging from 1 in heartburn to 185 in 
hypertension (Table 1). The strongest associations based on common genes were found 
between mumps  nd polymy lgi , Crohn‟s dise se and ulcerative colitis, asthma and nasal 
allergies, and diabetes and hypertension (average JI= 0.124, range, 0.10–0.14) (Additional 
file 1: Table S3). The average number of biological processes and pathways shared between 
morbidities was 147.2 (range 9-386) and 29.7 (range 4-96). 
DisGeNET curated subset showed 73 genes associated with PC; half of these had 
disease specificity >0.75 and disease pleiotropy <0.30 (Additional file 1: Table S4). Twenty-
two out of the 73 genes (range 0-10) were also associated with other morbidities (Tables 1 
and 2), with ABO, SPINK1, PDX1, TFPI2, and STK11 showing the highest disease specificity 
and the lowest disease pleiotropy (DSI > 0.73 and DPI < 0.41). 
Fifteen morbidities were associated with PC through at least one gene, including 
peptic ulcer (JI=0.055), hypertension (JI=0.04), and ulcerative colitis (JI=0.04) that showed 
the most robust genetic relationship with PC (Table 1 and Figure 1). PC and hypertension had 
the highest number of shared biological processes (N=69); 125 unique biological processes 
were shared between PC and seven morbidities (Table 3). The biological process that was 
sh red between PC  nd more morbidities w s „neg tive regul tion of f t cell differenti tion‟. 
Twenty-one unique pathways were shared between PC and at least one morbidity with peptic 
ulcer sharing the highest number of pathways (N=16) (T ble 3). „TNF signalling‟  nd 
„TNFR1-mediated proapoptotic signalling‟ p thw ys were sh red between PC, T2D, peptic 
ulcer, and rheumatoid arthritis.  
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Giving the unexpected genetic link observed between AIDs and PC in DisGeNET and 
the existing scarce literature regarding this relationship 
4,9,25
, we decided to focus on these 
conditions in the PanGenEU epidemiological study and assessed the association with PC risk 
of nine AIDs with enough available data in the study population. Overall, 16.2% of controls 
reported having any AID in comparison to 13% reported by PC cases (Table 4). 
Multivariable logistic regression models showed that having any AID was associated with a 
significant reduced risk of PC (OR=0.74, 95%CI 0.58-0.93). Furthermore, the number of 
AIDs was significantly associated with a reduced PC risk trend (P trend = 0.002). Having any 
systemic or organ-specific AID was significantly associated with lower PC risk (OR=0.74, 
95%CI: 0.55-0.99, and OR=0.71, 95%CI 0.52-0.97, respectively). Among organ-specific 
diseases, having any one or more gastrointestinal AID was borderline associated with a low 
risk of PC (OR= 0.51, 95%CI 0.26-1.00). Analysis of individual AIDs showed significant 
and borderline significant associations with polymyalgia rheumatica and rheumatoid arthritis, 
respectively (OR=0.4, 95%CI: 0.18-0.89, and OR=0.73, 95%CI: 0.53-1.00). The association 
with any AID and >2 AIDs was maintained after inflammatory/pain killer treatment 
adjustment. No significant interactions were observed. 
 
Discussion  
We used a systems medicine approach to unravel the shared genetic background of PC and its 
associated co-morbidities. We show that out of the 26 morbidities of interest 15, including 
five AIDs, share a genetic background with PC according to the available data in DisGeNET, 
a fact that points to the involvement of immune dysregulation processes in PC pathogenesis. 
We confirmed the AID-PC association first observed in DisGeNET with the results from a 
large European case-control study population. 
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We observed that some morbidities previously associated with PC risk in the 
literature
9,26
 were also sustained at a genetic level sharing 22 genes with PC according to 
DisGeNET. Many of the genes highlighted in these explorations are relevant in pancreatic 
carcinogenesis (e.g. KRAS, ABO, BRCA2, STK11), while others are important players in 
inflammatory process (e.g. PTGS2, TGFB1, CXCL8)
27,28
. Likewise, many of the biological 
processes and pathways shared between these morbidities and PC are essential in 
inflammation and carcinogenesis. 
Disentangling the underlying mechanisms behind multimorbidities could improve 
disease prevention and patient management. Growing evidence suggests that integrative 
approaches help to better grasp disease complexity. New bioinformatics tools such as 
DisGeNET that generate multimorbidity networks based on gene-disease associations 
available from public datasets have become ideal for this purpose. A main limitation of this 
approach is that we can only consider gene-disease associations that have been published, 
curated and registered in databases. In our study, the few or lack of genetic associations 
between some morbidities may result from either a real absence of a genetic association or 
due to the incomplete knowledge about the genetic basis of human diseases. Therefore, we 
cannot rule out that some associations could have been missed due to the still limited 
spectrum of the information available. In this respect, we relied on the JI to overcome 
problems due to differences in how well studied some diseases are over others. Conversely, 
we cannot exclude the possibility that other morbidities not included in our bioinformatics 
analysis could be also genetically associated with PC. Assessing the common genetic 
background of other autoimmune morbidities and PC might help us to gather an even broader 
view of this malignancy and further increase our understanding of PC. 
Applying a systems approach to explore PC-associated multimorbidities has the 
potential to generate new hypotheses. Among the 15 morbidities found genetically associated 
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with PC, rheum toid  rthritis, lupus erythem tosus, ulcer tive colitis, Crohn‟s dise se,  nd 
scleroderma have been vaguely studied as risk factors of PC (Additional file 1: Figure S2). 
Previous work suggested that AIDs could predispose individuals to cancer. Additionally, 
paraneoplastic autoimmune syndromes have been described
29
. Current studies point to an 
association between certain AIDs and an increased risk of different types of cancers such as 
small intestine and oesophageal cancers with celiac disease, or haematological neoplasms 
with rheumatoid arthritis, systemic lupus erythematous, and scleroderma
11,17,19,30
. Yet, some 
of these AIDs have been associated with a decreased risk of other cancers such as breast and 
colorectal
18,19,31
, suggesting that the association may not be the same for all cancer types. For 
PC, the information is limited and conflicting.  
The association with pernicious anaemia seems to be the only one that has been 
purposely analysed in the context of PC, but no significant association was reported 
32
. Other 
studies exploring the association between specific AIDs and cancer overall mainly relying on 
registry data and reporting on PC, appear inconclusive
22,33–35
. The retrospective nature of 
most of these studies limits the adjustment for potential confounders. Moreover, to our 
knowledge, no study explored the association between PC and scleroderma. Our study design 
allowed us to account for confounding and interaction of a broad set of factors.  
We report a significant negative association between suffering one or more of the nine 
AIDs under study and PC risk. We observed that the estimate further decreased in subjects 
reporting >2 AIDs, with a significant negative trend. Independent analysis of each AID 
showed a significant association between polymyalgia rheumatica and rheumatoid arthritis 
with lower PC risk. However, these analyses were limited by sample size. Other studies have 
reported a lack of signific nt  ssoci tion between lupus or  ddison‟s dise se  nd PC 
13,17,20,22,23,31,36
. Contradictory results have been published regarding pernicious anaemia, 
Crohn‟s dise se,  nd ulcer tive colitis with some studies reporting no signific nt 
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association
16,22,32,33,35
 while others showing a significant increased PC risk
12,15,34
. For celiac 
disease, studies have reported both significantly reduced and increased risk of PC
18,22
, but a 
recent meta-analysis showed no significant association
11
. Furthermore, most studies have 
described a lack of association between rheumatoid arthritis and PC risk
22,37–39
. However, a 
study performed with the Scottish Cancer Registry reported a significant negative association 
between rheumatoid arthritis and PC among women but not among men
21
; in our study, no 
interaction was observed with gender. Other studies ev lu ting ulcer tive colitis, Crohn‟s 
disease, rheumatoid arthritis, polymyalgia and giant cell arthritis, and pernicious anaemia by 
time since diagnosis reported significantly increased PC risk mostly restricted to subjects 
reporting <1 year difference between AIDs and cancer diagnoses; when >1 year between 
diagnoses is reported, loss of significance is commonly observed 
12,15,34,40,41
. Comparison 
with the existing literature is challenging since, to our knowledge, this is the first study 
incorporating confounders and combining different AIDs into single variables. Although the 
epidemiological literature is inconclusive regarding their link, atopy and autoimmunity are 
known hypersensitive reactions of the immune system
42
. Accordingly, our enrichment 
analyses showed that atopic and autoimmune diseases share several immune-related 
biological processes and pathways (Additional file 1: Figure S3). The importance of the 
immune environment in which tumours develop is further strengthened by the emerging 
evidence of the role of immune checkpoint inhibition as a potent therapeutic strategy in a 
wide variety of tumours. However, only a fraction of patients respond to such therapies and 
there is an urgent need to identify predictors of response
43
. These results, and our previous 
findings of a reduced PC risk among subjects with atopic conditions
7
, strongly suggest that 
immune recognition of neoantigens, its quantity and quality could contribute to modulate the 
immune response to emerging preneoplastic clones
44
.  
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Conversely, while autoimmune pancreatitis is an AID suggested to develop into 
chronic pancreatitis, its link with PC risk has not been established
45,46
. Moreover, it is 
reasonable to expect a different type of association in AIDs that result in localized damage to 
the pancreas. Moreover, one could hypothesize that the decreased risk of certain cancers and 
AIDs could be the consequence of confounding by particular treatments. However, we lacked 
information about treatment for AIDs. In vivo studies suggest that anti-TNF therapy could 
inhibit pancreatic tumour growth and metastasis
47,48
, though its link with carcinogenesis is 
not completely elucidated
49,50
. Combination of gemcitabine with TNF inhibitors at doses 
approved for AID treatment does not seem to significantly improve gemcitabine treatment in 
PC patients
51
. We show that further adjusting for anti-inflammatory/pain relief treatment 
results in the loss of significance for some associations. While these results could suggest a 
potential confounding effect, additionally supporting common pathways between PC and 
AID, we cannot completely rule out chance findings giving the small effect of the treatment 
adjustment on the estimates and the sustained significance of the main variables. 
The interpretation and generalization of these results must be done carefully. While 
the combination of AIDs into categories helped us to overcome the problem of statistical 
power, our study size is limited for the inquiry of specific disorders and stratified analysis. 
Additionally, considering that our information is self-reported, some degree of disease 
misclassification might have occurred resulting in a lower rate of false positive than false 
negative reports, probably those with less severe conditions, which would attenuate the risk 
estimates.  It remains necessary to replicate these associations; in this context register-based 
information and electronic Medical Records could be an ideal setting to gather a longitudinal 
view of the assicuation between AIDs and PC.  
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To our knowledge this is the first study exploring in depth the association between 
several autoimmune diseases and PC risk. This report highlights the importance of 
multimorbidities in PC risk. Many of these results are confirmatory of the mechanistic 
notions about pancreatic carcinogenesis. Importantly, common genetic association between 
PC and AIDs was identified through a bioinformatics approach, which was further 
characterized in an epidemiological setting as a negative association between AIDs and PC 
risk, opening new venues to explore and increase our understanding of PC risk potentially 
impacting the prevention and treatment strategies for this deadly cancer. 
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Table 1. Number of concept unique identifiers, total genes, common genes with pancreatic 
cancer and respective Jaccard indexes for diseases under study. 
 
Disease1 Number of CUIs Genesdis1 Common Genes JI P val
a 
Peptic ulcer 3 23 5 0.0549 < 10-5 
Hypertension 9 185 10 0.0403 < 10-5 
Ulcerative colitis 1 57 5 0.04 < 10-5 
Acid regurgitation 2 5 2 0.0263 < 10-5 
Asthma 6 83 5 0.0331 0.0001 
Obesity 10 156 7 0.0315 0.0001 
Type 2 diabetes 3 124 6 0.0314 0.0002 
H.pylori 2 5 1 0.013 0.0009 
Rheumatoid arthritis 1 123 5 0.0262 0.001 
Chronic pancreatitis 1 6 1 0.0128 0.0013 
Periodontitis 4 9 1 0.0123 0.0032 
Hyperthyroidism 4 10 1 0.0122 0.0037 
Scleroderma 12 11 1 0.012 0.0048 
Crohn‟s dise se 3 41 2 0.0179 0.0065 
Lupus erythematosus 6 68 2 0.0144 0.0250 
Nasal allergies 3 17 0 0 - 
Skin allergies 9 43 0 0 - 
Hypercholesterolemia 12 40 0 0 - 
Heartburn 1 1 0 0 - 
Hypothyroidism 2 3 0 0 - 
Mumps 1 9 0 0 - 
Pernicious anaemia 1 2 0 0 - 
Gallstones 3 6 0 0 - 
Celiac disease 1 28 0 0 - 
Polymyalgia 3 7 0 0 - 
Addison disease 1 11 0 0 - 
a
Empirical p value calculated after performing 50,000 bootstraps  
CUI: Concept unique identifier, JI= Jaccard index  
   Note: pancreatic cancer CUIs = 3, Genes = 73. 
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Table 2. Common genes between pancreatic cancer and other diseases in DisGeNET. 
 
Gene  Ndis Diseases 
TNF 9 Asthma, obesity, type 2 diabetes, hypertension, peptic ulcer, rheumatoid arthritis, 
scleroderm , Crohn‟s dise se, ulcer tive colitis 
MMP9 6 Asthma, obesity, peptic ulcer, periodontitis, lupus erythematosus, ulcerative colitis 
PTGS2 6 
Obesity, hypertension, peptic ulcer, acid regurgitation, rheumatoid arthritis, lupus 
erythematosus 
SOD2 5 Obesity, type 2 diabetes, hypertension, hyperthyroidism, rheumatoid arthritis,  
PPARG 4 Obesity, type 2 di betes, hypertension, Crohn‟s disease 
TGFB1 4 Asthma, type 2 diabetes, hypertension, peptic ulcer 
AHR 2 Hypertension, rheumatoid arthritis 
CDH1 2 Ulcerative colitis, H. pylori infection 
CXCL8 2 Acid regurgitation, Ulcerative colitis 
PTEN 2 Asthma, hypertension 
ABO 1 Peptic ulcer 
BCL2L1 1 Type 2 diabetes 
CNR1 1 Obesity 
DPYD 1 Obesity 
HIF1A 1 Hypertension 
PDX1 1 Type 2 diabetes 
PLAU 1 Asthma 
SPINK1 1 Chronic pancreatitis 
STAT3 1 Ulcerative colitis 
STK11 1 Hypertension 
TFPI2 1 Rheumatoid arthritis 
TP53 1 Hypertension 
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Table 3. Number of unique biological processes and pathways shared between each disease and any 
other diseases and number of processes shared between the diseases and pancreatic cancer. 
 
Disease 
N unique processes 
annotated 
N processes 
shared with PC 
N unique pathways 
annotated 
N pathways 
shared with PC 
Hypertension 386 69 96 0 
Type 2 diabetes 340 18 54 10 
Asthma 278 14 46 0 
Rheumatoid arthritis 277 13 36 7 
Crohn‟s dise se 266 0 36 0 
Obesity 251 31 37 0 
Ulcerative colitis 195 18 30 0 
Peptic ulcer 177 31 37 16 
Lupus erythematosus 169 0 32 0 
Skin allergies 139 0 26 0 
Pancreatic cancer 125 - 21 - 
Hyperthyroidism 50 0 12 0 
Hypercholesterolemia 36 0 16 0 
Celiac disease 30 0 12 0 
Mumps 24 0 4 0 
Addison disease 17 0 14 0 
Polymyalgia 17 0 16 0 
Scleroderma 10 0 6 0 
Nasal allergies 9 0 0 0 
PC: pancreatic cancer 
Note:  Only diseases for which biological processes and/or pathways were found through enrichment analyses 
are presented. 
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Table 4. Odds ratios for the association between autoimmune diseases and pancreatic ductal adenocarcinoma. 
 
  Cases   Controls                     
  N=1705 % N=1084 %   OR
a
 95%CI   OR
b
 95%CI   OR
c
 95%CI 
Autoimmune diseases             
No 1483 86.9 908 83.8  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Any 222 13.0 176 16.2  0.78 [0.62;0.98]  0.74 [0.58;0.93]  0.78 [0.61;0.99] 
Number of AID              
No 1483 86.9 908 83.8  Ref. Ref.  Ref. Ref.  Ref. Ref. 
1 201 11.8 146 13.5  0.85 [0.66;1.08]  0.81 [0.63;1.04]  0.85 [0.66;1.09] 
>2 21 1.2 30 2.8  0.45 [0.25;0.83]  0.39 [0.21;0.73]  0.44 [0.24;0.81] 
P trend
d
       0.009   0.002   0.01 
Type of AID              
None 1483 86.9 908 83.8  Ref. Ref.       
Systemic only 120 7.0 86 7.9  0.85 [0.62;1.16]  0.78 [0.58;1.08]  0.83 [0.60;1.15] 
Organ-specific only 88 5.2 73 6.7  0.77 [0.55;1.08]  0.76 [0.54;1.07]  0.78 [0.55;1.11] 
      Hematologic 65  3.8  53  4.9   0.82 [0.56;1.21]  0.80  [0.54;1.18]   0.82 [0.55;1.21] 
      Gastrointestinal 20  1.2  15  1.4   0.58 [0.25;1.32]  0.60  [0.26;1.37]   0.64 [0.28;1.46] 
      Endocrine 2  0.1  1  0.1   1.84 [0.16;2.11]  2.65  [0.23;3.07]   2.91 [0.25;3.34] 
      Mixed organ-specific 1  0.1  4  0.4   0.28 [0.03;2.64]  0.29  [0.03;2.74]   0.29 [0.03;2.85] 
Both systemic and localized 14 0.8 17 1.6  0.50 [0.24;1.07]  0.42 [0.19;0.90]  0.48 [0.22;1.05] 
Systemic AID              
No 1571 92.1 981 90.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Any 134 7.9 103 9.5  0.81 [0.60;1.08]  0.74 [0.55;0.99]  0.79 [0.59;1.07] 
Organ-specific AID              
No 1603 94 994 91.7  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Any 102 6 90 8.3  0.73 [0.53;0.99]  0.71 [0.52;0.97]  0.74 [0.54;1.02] 
Gastrointestinal AID             
No 1679 98.5 1059 97.7  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Any 26 1.5 25 2.3  0.51 [0.26;0.99]  0.51 [0.26;1.00]  0.55 [0.28;1.09] 
Lupus              
No 1696 99.5 1081 99.7  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 9 0.5 3 0.3  1.91 [0.48;7.53]  2.08 [0.51;8.44]  2.04 [0.49;8.39] 
Scleroderma             
No 1697 99.5 1080 99.6  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 8 0.5 4 0.4  0.91 [0.23;3.54]  0.81 [0.20;3.20]  0.83 [0.21;3.25] 
Polymyalgia              
No 1692 99.2 1065 98.3  Ref. Ref.  Ref. Ref.  Ref. Ref. 
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Yes 13 0.8 19 1.8  0.42 [0.20;0.92]  0.40 [0.18;0.89]  0.46 [0.21;1.04] 
Pernicious anemia             
No 1630 95.6 1014 93.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 75 4.4 70 6.5  0.75 [0.53;1.06]  0.72 [0.51;1.02]  0.75 [0.53;1.07] 
Crohn's disease             
No 1701 99.8 1079 99.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 4 0.2 5 0.5  0.26 [0.05;1.46]  0.32 [0.05;1.94]  0.36 [0.58;2.24] 
Celiac disease              
No 1698 99.6 1078 99.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 7 0.4 6 0.6  0.54 [0.15;1.95]  0.63 [0.18;2.17]  0.62 [0.18;2.19] 
Addison's disease             
No 1698 99.6 1078 99.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 7 0.4 6 0.6  0.89 [0.30;2.68]  0.91 [0.29;2.81]  0.96 [0.31;2.99] 
Rheumatoid arthritis             
No 1597 93.7 1000 92.3  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 108 6.3 84 7.8  0.81 [0.59;1.11]  0.73 [0.53;1.00]  0.78 [0.56;1.08] 
Ulcerative colitis             
No 1690 99.1 1068 98.5  Ref. Ref.  Ref. Ref.  Ref. Ref. 
Yes 15 0.9 16 1.5  0.55 [0.24;1.30]  0.49 [0.21;1.16]  0.54 [0.23;1.30] 
a
 Adjusted for age (continuous), sex and country            
b
 Model adjusted for age (continuous), sex, country, smoking (pack/years, tertiles based on the population distribution and alcohol status (never, former, current) 
c
 Model adjusted for age (continuous), sex, country, smoking (pack/years, tertiles based on the population distribution, alcohol status (never, former, current), and treatment 
 (no treatment, aspirin only, NSAIDs only, paracetamol only, corticosteroids only, and more than one treatment type) 
d
Trend was calculated using number of AID as a continuous variable (range from 0 to 4) 
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Figure 1. Gene network of medical conditions associated with PC through common 
genes. A) Network of diseases that share genes with pancreatic cancer and all corresponding 
connections; B) Network of diseases that share genes with pancreatic cancer, only 
connections with pancreatic cancer shown. Edge width represents the Jaccard index for each 
disease pair; Jaccard indexes were multiplied by 100 in order to allow better visualization. 
Node size represents the number of genes obtained through DisGeNET for each medical 
condition. 
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